Reaction
Retinal Tear reporting signals
As of the last recalculation, Retinal Tear appears in 2,420 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 45.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 134 | 45.9 | 46.1 |
| Prednisolone Acetate | 19 | 15.9 | 15.9 |
| Faricimab | 12 | 12.8 | 12.8 |
| Aflibercept | 43 | 12.1 | 12.1 |
| Carboxymethylcellulose Sodium | 13 | 12.0 | 12.0 |
| Dorzolamide Hydrochloride And Timolol Maleate | 10 | 10.9 | 10.9 |
| Upadacitinib | 65 | 7.0 | 7.0 |
| Cladribine | 7 | 6.3 | 6.3 |
| Timolol Maleate | 7 | 6.1 | 6.1 |
| Latanoprost | 32 | 5.5 | 5.5 |
| Timolol | 7 | 5.0 | 5.0 |
| Brimonidine Tartrate | 10 | 4.8 | 4.8 |
| Bimatoprost | 16 | 4.8 | 4.8 |
| Bosutinib | 5 | 4.8 | 4.8 |
| Risankizumab-Rzaa | 42 | 4.5 | 4.5 |
| Bevacizumab | 60 | 4.2 | 4.2 |
| Lifitegrast | 8 | 4.2 | 4.2 |
| Pazopanib Hydrochloride | 13 | 4.1 | 4.2 |
| Brinzolamide | 4 | 4.0 | 4.0 |
| Oral Semaglutide | 29 | 3.4 | 3.4 |
| Fingolimod Hcl | 31 | 3.1 | 3.1 |
| Fremanezumab-Vfrm | 4 | 3.0 | 3.0 |
| Vemurafenib | 4 | 2.9 | 2.9 |
| Galcanezumab-Gnlm | 4 | 1.1 | 1.1 |
| Tirzepatide | 19 | 1.0 | 1.0 |